small medium large |  
print   |   Bookmark & Share share
Profile Image

Investigator

Prashant Chittiboina, M.D., M.P.H

Neurosurgery Unit for Pituitary and Inheritable Diseases

Surgical Neurology Branch
Building 10 Room 3D20
10 Center Dr
Bethesda MD 20892-1414
Office: 301-496-5728

Fax: 301-402-0380
prashant.chittiboina@nih.gov

Dr. Chittiboina earned his M.D. from Goa University (India) in 2000 and a Master of Public Health from Idaho State University in 2004. He completed his residency in neurosurgery at Louisiana State University in 2012. During his residency, Dr. Chittiboina also completed a year-long research fellowship studying neuro-vascular disease. He came to NINDS in 2012 as a fellow, becoming a Staff Clinician in the Surgical Neurology Branch in 2013. He started his translational research program as an Assistant Clinical Investigator in 2015 followed by a Tenure Track position in April 2020. His laboratory studies neuroendocrine diseases that cause nervous system morbidity including as pituitary adenomas, Neurofibromatoses and von Hippel Lindau disease. His current work is focused on changing the outcomes of neurosurgical disorders through improved imaging.

As an neurosurgeon and investigator within NINDS, I manage patients with pituitary tumors causing Cushing’s disease (CD), and tumors of the central nervous system caused by the inheritable tumor syndromes such as Neurofibromatosis type 2 (NF2) and von Hippel Lindau disease (VHL). My research interests are informed by the challenges in managing the care of these patients. My time is evenly split between clinical care and research related activities. 

Approximately 50% of my clinical practice and 80% of my research activities are focused on Cushing’s disease. CD is caused by millimeter-sized pituitary corticotroph adenomas (corticotropinomas) that secrete adrenocorticotropic hormone (ACTH). CD leads to significant morbidity, and early mortality due to excessive cortisol release by the adrenal glands. Both the diagnosis and treatment of CD are challenging clinical problems. In collaboration with NICHD, NIDDK and the Clinical Center (CC), we have one of world’s largest ongoing clinical experiences in adult and pediatric CD. Overall, we have applied translational research strategies to understand the tumor biology1,2 and have applied these insights to improve the diagnosis3–6 and clinical care7,8 of patients with CD.

NF2 and VHL are two of the most common inheritable tumor syndromes of the central nervous system. I lead natural history clinical trials for NF2 and VHL. Patients with NF2 and VHL have challenging clinical questions that lead to a 50% clinical and 20% research time activity allocation within my Unit.

Staff Image
  • Reinier Alvarez, M.D.
    MRSP Scholar

  • David Asuzu, M.D., Ph.D.
    Clinical Fellow

  • Elizabeth Hogan, M.D.
    Clinical Fellow

  • Debjani Mandal, Ph.D.
    Contract Scientist

  • Maytal Silberberg, RN, BSN, CCRP
    Student

  • 1) Lu, J et al (2018)
  • Repurposing propranolol as an antitumor agent in von Hippel-Lindau disease
  • J. Neurosurg, doi:10.3171/2018.5.jns172879, 9-Jan
  • 2) deTorres, A. T. A. T et al (2018)
  • Audiologic Natural History of Small Volume Cochleovestibular Schwannomas in Neurofibromatosis Type 2
  • Otol. Neurotol, C, 1
  • 3) Ironside, N et al (2018)
  • Earlier post-operative hypocortisolemia may predict durable remission from Cushing’s disease
  • Eur. J. Endocrinol, 178
  • 4) Lu, J et al (2017)
  • Corticotropin releasing hormone can selectively stimulate glucose uptake in corticotropinoma via glucose transporter 1
  • Mol. Cell Endocrinol, doi:10.1016/j.mce.2017.10.003, 10-Jan
  • 5) Lu, J et al. (2017)
  • Histone deacetylase inhibitor SAHA is a promising treatment of Cushing disease
  • J. Clin. Endocrinol. Metab, 102, 2825-2835
  • 6) Chatain, G. P et al (2017)
  • Potential utility of FLAIR in MRI-negative Cushing’s disease
  • J. Neurosurg, doi:10.3171/2017.4.JNS17234, 9-Jan
  • 7) Abhik, R.-C et al (2017)
  • Somatostatin receptor expression on von Hippel-Lindau-associated hemangioblastomas offers novel therapeutic target
  • Sci. Rep, 7, 40822
  • 8) Asuzu, D et al (2017)
  • Normalized Early Postoperative Cortisol and ACTH Values Predict Nonremission After Surgery for Cushing Disease
  • J. Clin. Endocrinol. Metab, 102, 2179-2187
  • 9) Chittiboina, P et al (2016)
  • Endosphenoidal coil for intraoperative magnetic resonance imaging of the pituitary gland during transsphenoidal surgery
  • J. Neurosurg, 125, 9-Jan
  • 10) Feldman, M. J. M. J. M. J et al (2016)
  • Loss of Quiescence in von Hippel-Lindau Hemangioblastomas is Associated with Erythropoietin Signaling
  • Sci. Rep, 6, 35486
  • 11) Chittiboina P, Lalith Talagala S, Merkle H, Sarlls JE, Montgomery BK, Piazza MG, Scott G, Ray-Chaudhury A, Lonser RR, Oldfield EH, Koretsky AP, Butman JA (2016)
  • Endosphenoidal coil for intraoperative magnetic resonance imaging of the pituitary gland during transsphenoidal surgery
  • J Neurosurg, 18, 1-9[Epub ahead of print] PubMed PMID: 26991390
  • 12) Mehta, G. U et al (2015)
  • Different imaging characteristics of concurrent pituitary adenomas in a patient with Cushing’s disease
  • J. Clin. Neurosci, 22, 891-894
  • 13) Chittiboina P, Heiss JD, Lonser RR (2015)
  • Accuracy of direct magnetic resonance imaging-guided placement of drug infusion cannulae
  • J Neurosurg, May;122(5):1173-9. , PubMed PMID: 25594325
  • 14) Mehta GU, Montgomery BK, Raghavan P, Sharma S, Nieman LK, Patronas N, Oldfield EH, Chittiboina P (2015)
  • Different imaging characteristics of concurrent pituitary adenomas in a patient with Cushing's disease
  • J Clin Neurosci, May;22(5):891-4. doi: 10.1016/j.jocn.2015.01.001, PubMed PMID: 25827866; PubMed Central PMCID: PMC4
  • 15) Chittiboina P, Montgomery BK, Millo C, Herscovitch P, Lonser RR (2015)
  • High-resolution(18)F-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for pituitary adenoma detection in Cushing disease
  • J Neurosurg, 2015 Apr;122(4):791-7 , PubMed PMID: 25479121
  • 16) Chittiboina, P., Montgomery, B. K., Millo, C., Herscovitch, P. & Lonser, R. R (2014)
  • High-resolution 18 F-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for pituitary adenoma detection in Cushing disease
  • J. Neurosurg, 122, 7-Jan
  • 17) Trivellin G, Daly AF, Faucz FR, Yuan B, Rostomyan L, Larco DO, Schernthaner-Reiter MH, Szarek E, Leal LF, Caberg JH, Castermans E, Villa C, Dimopoulos A, Chittiboina P, Xekouki P, Shah N, Metzger D, Lysy PA, Ferrante E, Strebkova N, Mazerkina N, Zatelli MC, Lodish M, Horvath A, de Alexandre RB, Manning AD, Levy I, Keil MF, Sierra Mde L, Palmeira L, Coppieters W, Georges M, Naves LA, Jamar M, Bours V, Wu TJ, Choong CS, Bertherat J, Chanson P, Kamenický P, Farrell WE, Barlier A, Quezado M, Bjelobaba I, Stojilkovic SS, Wess J, Costanzi S, Liu P, Lupski JR, Beckers A, Stratakis CA (2014)
  • Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation
  • N Engl J Med, 18;371(25):2363-74, PubMed PMID: 25470569
View Pubmed Publication
View/Hide All Publications